Background: Radioimmunotherapy (RIT) has been approved for the treatment of B-cell non-Hodgkin lymphomas in the United
Introduction
The concept of radiolabeled antibodies targeted against tumor cells is hardly novel, having been fi rst described in the early 1950s. 1 Initially, investigators utilized radiolabeled polyclonal antibodies from various mammalian species for radioimmunodetection and the fi rst attempts at radioimmunotherapy (RIT). 2, 3 In 1975, Köhler and Milstein 4 developed hybridoma techniques that paved the way to the production of monoclonal antibodies. Within a few years, early radiolabeled monoclonal antibodies were reported to eliminate melanomas in a murine model. 5, 6 Soon afterward, the fi rst clinical human experiences with RIT were conducted. 7 Results from many of these early clinical studies of RIT were somewhat mixed, owing to the relatively modest radiosensitivity of epithelial cancers to lowdose radiation, the heterogeneous expression of target antigens in normal tissues, and the immunogenicity of these typically murine or lupine antibodies, preventing efforts at repeat dosing. These and other fundamental challenges for RIT have been compre-tumor dose is inversely proportional to the radius of the tumor mass, making the treatment of bulky tumor burden impractical for RIT but promising for micrometastatic disease. [21] [22] [23] Due to its early characterization and ubiquity of expression in CRC, 24 CEA has been the most common target for RIT in this disease. Lane et al 25 reported one of the earliest human trials of an anti-CEA radiolabeled antibody. Seventeen patients with CRC received the murine 131 I-A5B7 anti-CEA antibody, either as the intact immunoglobulin (Ig)-G form or as the F(abʹ) 2 fragment. This study reported 1 complete response (CR) and 1 PR. One important observation was that the smaller antibody fragments localized to tumor faster than did IgG.
Another important anti-CEA antibody, neutrophil proteinase-4 (NP-4), has been extensively evaluated. A phase I/II trial of 131 I-NP-4, a murine IgG 1 antibody, treated 57 patients, 29 of whom had CRC. 26 A single objective response was seen in the study, with 4 patients exhibiting minor responses. The same group then examined the F(abʹ) 2 fragment of this antibody in a small phase I trial with 13 patients, 8 of whom had CRC. 27 All patients had a relatively small burden of disease with no mass larger than 3 cm in diameter. Four patients exhibited stable disease (SD) lasting up to 7 months.
MN-14 is a murine IgG monoclonal antibody against CEA with an order-of-magnitude greater affi nity for the antigen than NP-4. Juweid et al 28 reported the results of a phase I trial of rhenium-188 ( 188 Re)-MN-14 in 10 patients with CRC. A fractionated approach was used due to the relatively short halflife of 188 Re, with 2 or 3 divided doses given to study participants to deliver higher doses with less toxicity than that seen with a 131 I-labeled antibody. The group reported a maximum tolerated dose (MTD) of 60 mCi/ m 2 , with the ability to deliver this on an outpatient basis. Two patients in the study developed HAMAs.
The concern over the potential immunogenicity posed by treatment with murine monoclonal antibodies led to the development of a humanized version of their anti-CEA antibody, humanized . Two studies have been reported in patients with small-volume disease. 29, 30 In both studies, 16% of patients exhibited an objective response, with 42% to 45% showing a mixed or minor response to RIT. The group also performed several studies of adjuvant 131 IhMN-14 following R0 resection of hepatic metastases in patients with CRC. [30] [31] [32] [33] The median disease-free survival (DFS) in these studies was approximately 18 months, with 5-year overall survival (OS) in nearly half of the treated patients.
The antibody cT84.66, a chimeric IgG anti-CEA antibody against the A3 epitope of CEA, is highly selective for tumor CEA expression and binds with great affi nity. 34 Wong et al [35] [36] [37] [38] have published several reports on cT84.66, and several phase I studies have been performed with this 90 Y-labeled antibody hensively reviewed elsewhere 8 and are beyond the scope of this review.
More recently, attention has turned to the development of RIT agents for the treatment of B-cell non-Hodgkin lymphomas, which are inherently radiosensitive and express antigens not typically found in normal tissue. Ibritumomab is a murine monoclonal antibody that binds to CD20, which is found on the surface of mature B cells and most B-cell malignancies. This antibody utilizes the linker-chelator tiuxetan to hold yttrium-90 ( 90 Y), a beta-emitting radioisotope, for the purpose of RIT. However, repeat dosing with 90 Y ibritumomab tiuxetan led to the development of human antimurine antibodies (HAMAs). A chimeric version of the antibody was produced -rituximab -that exhibited a signifi cant antilymphoma effect in the absence of the radioisotope and without the development of HAMAs. In 1997, rituximab was the fi rst monoclonal antibody to receive approval by the US Food and Drug Administration (FDA). 9 During the next several years, the development of RIT agents for B-cell non-Hodgkin lymphoma continued, which led to the FDA approval of 90 11 Both agents are indicated for relapsed or refractory low-grade B-cell non-Hodgkin lymphomas, while 90 Y ibritumomab tiuxetan is also used in the frontline setting following at least a partial response (PR) to induction chemoimmunotherapy. Several other RIT agents for lymphomas have been investigated. Perhaps the most promising is 90 Y epratuzumab tetraxetan, which is currently in clinical trials for aggressive B-cell lymphomas, 12 newly diagnosed follicular lymphoma, and B-cell acute lymphoblastic leukemia (NCT01101581, NCT01147393, and NCT01354457). The role of RIT for B-cell non-Hodgkin lymphomas has recently been reviewed. 13 In general, solid tumors are much less radiosensitive than B-cell lymphomas, requiring higher delivered doses for signifi cant clinical effi cacy.
14 Here, we review major attempts at solid tumor RIT and emerging techniques for improving the therapeutic window of this modality in the treatment of advanced solid malignancies.
Colorectal Cancer
Cancer of the colon and rectum is the third most common form of malignancy in the United States, accounting for 9% of all cancer cases. 15 In 2012, an estimated 143,460 new cases were diagnosed and 51,690 patients died of types of colorectal cancer (CRC). 15, 16 Some of the earliest RIT experiences have been in CRC, principally due to the early discovery of carcinoembryonic antigen (CEA) and tumor-associated glycoprotein 72 (TAG-72), both of which are often highly expressed in CRC tumors. Beginning in the late 1980s, investigators began to examine 131 I-labeled anti-CEA antibodies and antibody fragments in xenograft models of metastatic CRC. [17] [18] [19] [20] In dosimetric studies, investigators quickly realized that the absorbed in patients with CRC, with minor responses ranging from 31% to 57%. 53 Most of the patients also received whole-liver external beam radiotherapy in conjunction with the RIT. One PR and 11 mixed responses or SD were reported. No signifi cant liver toxicity was seen with this combination therapy. The chimeric version of this antibody, 125 I-17-1A, was evaluated in a phase I study, with 28 patients with CRC receiving 20 to 250 mCi. 54 Ten patients who were reported to have SD from the RIT. No signifi cant DLTs were reported in either study of RIT with the 17-1A antibody.
NR-LU-10 is a murine IgG against Ep-CAM and has been evaluated in the phase I setting of 15 patients (10 with CRC). 45 Labeled with 186 Re, the antibody was not associated with objective responses, and all patients developed HAMAs. The MTD was found to be 90 mCi/m 2 . The chimeric version of this antibody, 186 Re-NR-LU-13, was evaluated in a small phase I study. 55 Patients were treated with 25 to 60 mCi/ m 2 . Two of the 9 patients had SD. The majority of patients demonstrated evidence of immunogenicity despite the chimeric nature of the antibody.
A33 is another antigen highly expressed by colonic epithelium and CRC and is also not shed into the circulation. Like Ep-CAM, an antibody binding to A33 is internalized. Two phase I/II studies have been reported using the murine IgG, A33. 56, 57 Welt et al 56 reported their experience with 131 I-A33 in 23 patients with CRC in which 3 patients exhibited a mixed response to therapy, with a reported MTD of 75 mCi/ m 2 . The same group also performed a similar trial in 21 patients with CRC using 125 I-A33. 57 All patients were chemorefractory and received from 50 to 350 mCi/m 2 . They reported a single mixed response and no DLTs. A humanized version of the antibody was reported as part of a phase I study of 15 patients with CRC in which the MTD was reported to be 40 mCi/ m 2 . 58 Four patients exhibited immunogenicity to the humanized antibody, and 4 patients demonstrated SD in response to RIT.
In summary, there is a rich clinical experience of early phase clinical trials reported for RIT in patients with CRC. Several promising targets have been identifi ed, including CEA, TAG-72, Ep-CAM, and A33. Overall, the results have been somewhat disappointing, with few objective responses. However, in the setting of minimal residual disease, some studies have demonstrated favorable progression-free survival (PFS) and OS compared with historic outcomes.
Breast Cancer
Breast cancer (BC) is the leading malignancy in women in the United States, with an estimated 226,870 new cases diagnosed in 2012, along with 39,510 deaths from the disease. 15, 16 BC is also one of the more radiosensitive solid tumors, with external beam radiation capable of eliminating microscopic residual disease following lumpectomy. 59, 60 Several promising antigenic targets have been identifi ed for RIT in BC, including CEA. T84.66, described above for its use in CRC, has also been studied in patients with BC. A phase I trial of 90 Y-diethylenetriaminepentaacetate (DTPA)-cT84.66 in 7 patients with BC was reported by Wong et al. 61 RIT was administered at 15 or 22.5 mCi/m 2 . No DLTs were reported, and all patients successfully engrafted following an autologous stem cell infusion. One PR and 2 cases of SD were described.
MUC-1, a mucin epitope, is commonly expressed on the surface of BC cells. Several reports reveal effi cient radioimmunodetection of BC using anti-MUC-1 monoclonal antibodies. [62] [63] [64] [65] Schrier et al 66 reported on a phase I trial of high-dose murine 90 Y-DTPA-BrE-3 and autologous stem cell rescue in 9 women with BC. Single RIT doses of 15 or 20 mCi/m 2 were given, with no DLTs. One-half of the patients with measurable disease exhibited objective PRs to therapy. 66 However, most patients developed HAMAs, limiting the ability to consider repeat dosing. A humanized version of the antibody has also been evaluated for use with stem cell support. 67 Two patients exhibited objective PRs; each patient had a mixed response and SD.
L6 is another antigen highly expressed on the surface of the majority of BC cells as well as some lung, prostate, and ovarian cancers and in the vascular endothelium. 68 Investigators have studied a chimeric anti-L6 monoclonal antibody ( 131 I-chL6) in patients with BC. Richman et al 69 reported the results of a phase I study of fractionated 131 I-chL6 RIT in the setting of high-dose therapy followed by autologous stem cell rescue. Three patients were treated with up to 3 cycles of RIT. One patient treated with cyclosporine did not develop HAMAs but the others did. 69 The authors concluded that fractionation may allow for total dose escalation with less normal tissue toxicity and that cyclosporine may have a role in reducing the immunogenicity of RIT. 69 The same group later reported the results of repeat dosing of 131 I-chL6, up to 4 monthly cycles, without stem cell support in 10 patients with BC. 70 Objective clinical responses were seen in one-half of those treated. 70 The anti-TAG-72 monoclonal antibody CC49 has also been evaluated in BC, labeled with either lutetium-177 ( 177 Lu) or 131 I. 49, 71, 72 Pretreatment with interferon alfa led to a nearly 50% increase in expression of TAG-72 on immunohistochemistry, which corresponded to a signifi cantly increased uptake of 131 I-CC49 in tumors. 71, 72 Patients exhibited 1 PR and 2 minor responses to therapy in a total of 15 participants. 71, 72 In summary, several active targets have been identifi ed in BC for RIT, including CEA, TAG-72, MUC-1, and L6. Modest responses have been seen, with greater responses in the setting of high-dose RIT followed by autologous stem cell rescue. Interferon alfa may have the ability to upregulate expression of key RIT targets in patients with BC. Murine antibodies result in a high expression of HAMAs, limiting repeat dosing strategies.
Prostate Cancer
Prostate cancer (PC) is the most common noncutaneous malignancy in men in the United States, with an estimated 241,740 new cases and 28,170 deaths from the disease in 2012. 15, 16 It has been nearly 30 years since the fi rst successful antibody targeting of PC. 73 Perhaps the earliest clinical use of therapeutic RIT was reported by Meredith et al, 74 who targeted TAG-72 with 131 I-CC49 in 15 patients with androgen-independent PC. The antibody localized well to known areas of metastatic disease with no signifi cant toxicity. However, there were no patients with a biochemical response, and all patients developed HAMAs. Of the patients with painful skeletal lesions, 60% described an improvement in their reported pain. 74 A follow-up study by the same group used interferon alfa to increase tumor localization of 131 I-CC49. 75 They found an absorbed dose in excess of 25 Gy in the majority of visualized tumors. Two patients exhibited minor responses, and pain relief from skeletal metastases was common in this study. No major toxicities were reported. The L6 antigen, described above as a BC target, has also been evaluated for PC. 76 O'Donnell et al 77 examined 90 Y-DOTA-chL6 in mice bearing PC xenografts and described a 100% response rate at an MTD of 150 mCi. Myelosuppression was seen but was fully reversible, and improved OS was seen in mice receiving the highest doses. The same group reported the results of a murine xenograft model, combining 90 Y-DOTAchL6 and taxane chemotherapy. This resulted in a 67% cure rate for mice receiving both RIT and docetaxel, a 20% cure rate with RIT plus paclitaxel, and there was no cure rate in RIT alone, chemotherapy alone, or in the control groups. 78 MUC-1 has also been shown to be upregulated in androgen-independent PC cells, making it a good target for RIT. 79 A murine monoclonal antibody, m170, was initially examined in 17 patients with metastatic, androgen-independent PC in a phase I, dose-escalation trial labeled with 90 Y. 80 No DLTs were reached, and toxicity was limited to reversible myelosuppression. A majority of patients with pain at study entry reported a signifi cant reduction in pain following therapy. The same group performed a phase I study of 90 Y-2IT-BAD-m170 combined with low-dose paclitaxel in patients with PC. 81 Two patients receiving combined modality therapy developed grade 4 neutropenia as opposed to none in the group receiving only RIT. Only 1 patient exhibited evidence of immunogenicity due to concurrent cyclosporine use.
Prostate-specifi c membrane antigen (PSMA) is another rational PC target for RIT. PSMA is a hormone-independent, transmembrane glycoprotein that is minimally shed into the circulation and rarely ex-pressed outside the prostate. 82 Once bound, PSMA becomes internalized into the PC cell, destined for endosomal recycling. CYT-356 (ProstaScint; Cytogen Corp, Princeton, NJ) is an 111 In-labeled monoclonal antibody against the 7E11-C5.3 epitope of PSMA and is commercially used for imaging of metastatic PC foci. Deb et al 83 reported the results of a phase I trial of escalating doses of 90 Y-CYT-356 in 12 patients with metastatic PC. The MTD was 9 mCi/m 2 . No objective responses were reported, but higher doses seemed to be associated with longer PFS. No immunogenicity was seen in any patient at 4 weeks.
J591, an IgG monoclonal antibody against the extracellular domain of PSMA, has also been evaluated in patients with PC. 84 Labeled with the alpha-emitter bismuth-213 ( 213 Bi), the antibody 213 Bi-J591 was fi rst described in a PC cell line and in athymic mice bearing PC xenografts, which is where it showed an ability to stop growth of PC spheroids in vitro and signifi cantly reduce prostate-specifi c antigen (PSA) in vivo. 85 Bander et al 86 reported on a phase I trial of 177 Lu-J591 in 35 patients with androgen-independent metastatic PC. The single-dose MTD was determined to be 70 mCi/m 2 and the repeat MTD was 30 mCi/m 2 for up to 3 doses. There was no evidence of immunogenicity. A majority of patients exhibited a reduction or stabilization of PSA levels in response to therapy. Milowsky et al 87 performed a similar phase I study using 90 Y-J591 in 29 patients with metastatic PC. The MTD was reported to be 17.5 mCi/m 2 . Six patients exhibited stabilization of PSA, and 2 had signifi cant drops in the tumor marker. The same group dosimetrically compared 177 Lu-J591 with 90 Y-J591 and reported that the absorbed dose to the bone marrow was approximately 3 times higher with 90 Y, which was largely a function of the higher mean path length of the emitted beta particle. 88 Ongoing phase II trials of 177 Lu-J591 are currently open for accrual for patients with androgen-independent PC (NCT00859781, NCT00195039).
In summary, a number of rational RIT targets have been described for PC, including TAG-72, L6, MUC-1, and PSMA. By contrast to most solid tumor types, patients with PC have exhibited some reasonable responses to RIT, particularly in the combined modality setting when delivered with taxane chemotherapy. Patients with PC who also have skeletal metastases experienced signifi cant pain relief, even with RIT alone. The most promising agent currently in active clinical trials is 177 Lu-J591, which targets PSMA.
Ovarian Cancer
Approximately 22,280 cases of ovarian cancer (OC) were diagnosed in the United States in 2012, with an estimated 15,500 deaths caused by the disease. 15, 16 Approximately 24 RIT constructs have been evaluated in preclinical and/or clinical studies. Intraperitoneal administration of RIT for advanced OC was fi rst described more than 25 years ago. 89 Human milk fat globule (HMFG) 1 is a murine monoclonal antibody directed against MUC-1. A phase I/II clinical trial of intraperitoneal 90 Y-HMFG1 suggested an extended PFS following CR to surgery and chemotherapy with RIT. 90 The follow-up randomized controlled trial of intraperitoneal 90 Y-HMFG1 showed no clinical benefi t in adding an RIT agent compared with standard care following a complete clinical remission after chemotherapy and surgery. 91 However, the study did show a decrease in intraperitoneal relapse rates. 92 Placental-like alkaline phosphatase (PLAP) is a surface membrane enzyme expressed in the majority of ovarian tumors. 93, 94 Hu2PLAP is a human IgG monoclonal antibody directed against PLAP and has been used clinically for the radioimmunodetection of ovarian tumors, labeled with 111 In and 123 I. Both labeled agents were shown to localize to PLAP-positive ovarian tumors with no signifi cant toxicity, and 2 of the 30 patients in the study exhibited immunogenicity. 95 No therapeutic studies using Hu2PLAP have been reported to date.
Trastuzumab is a humanized IgG monoclonal antibody directed against the extracellular domain of the oncoprotein human epidermal growth factor receptor 2 (HER-2)/neu, commonly overexpressed in breast, ovarian, and gastrointestinal tumors. 96 This antibody has been labeled with several radionuclides for preclinical and clinical studies, including 90 There is an ongoing phase I study of intraperitoneal 212 Pb-trastuzumab for patients with advanced OC with positive pelvic washings or peritoneal studding. 105 Pertuzumab is a human monoclonal antibody directed against the HER-2 dimerization domain. Labeled with 177 Lu, this agent has been evaluated in a murine xenograft model. Mice treated with 177 Lupertuzumab exhibited a delayed tumor progression without evidence of signifi cant toxicity.
106
As with previously described solid tumors, TAG-72 is frequently expressed on the surface of ovarian tumors. CC49, labeled with 90 Y or 177 Lu, has been evaluated in a number of OC clinical studies. Meredith et al 107 reported the results of a phase I study in 12 patients with advanced OC, intraperitoneally delivering 177 Lu-CC49. No MTD was reached up to 30 mCi/m 2 , and RIT was well tolerated, with only mild myelosuppression. Only 1 of 8 patients with gross disease showed an objective response, but 3 of the 4 patients with occult disease remained without evidence of progression after 18 months. The same group reported on a phase I/II study of intraperitoneal 177 Lu-CC49 in 27 chemotherapy-refractory patients. 108 As with the prior study, only 1 patient with gross disease responded, but 80% of those with occult disease remained disease-free for up to 3 years; the MTD was determined to be 45 OC125 is a murine F(abʹ) 2 monoclonal antibody fragment directed against CA-125, an OC tumor marker. Three clinical studies have been published using this antibody for intraperitoneal administration. [110] [111] [112] In the fi rst study, 90 Y-OC125 was infused into 5 participants going for a second-look surgery. 110 Intraoperative scintigraphy was performed to localize tumor foci for additional resection. In addition, the investigators performed normal organ dosimetric measurements that showed most of the infused dose remaining within the intraperitoneal space and approximately a 6:1 concentration of tumor to normal tissue. Mahé MOv18 is a murine or chimeric monoclonal antibody directed against a folate-binding protein present on the surface of nearly all ovarian carcinomas. 113, 114 Although the antibodies specifi cally target the folatebinding protein, signifi cant heterogeneity was found between patients and even between tumor foci within patients following RIT, perhaps owing to differences in folate-binding protein in the tumors. 115 The same group examined differences between intravenous and intraperitoneal administration of the 131 I-labeled antibody and found no targeting benefi ts to intraperitoneal delivery but possibly less hematologic toxicity.
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Another intriguing potential target for RIT in OC is the cell-surface sodium-dependent phosphate transport protein 2b, recognized by the murine IgG MX35.
117,118 A Swedish group 119 has performed extensive preclinical studies on intraperitoneal delivery of the alpha-emitter-labeled antibody, 211 At-MX35 F(abʹ) 2 . Nude mice inoculated intraperitoneally with OC xenografts were treated with either the targeted agent 211 At-MX35 F(abʹ) 2 or the nonspecifi c 211 At-rituximab F(abʹ) 2 . The alpha-labeled MX35 was signifi cantly more effective at tumor kill, with a relatively higher mean absorbed dose (> 22 Gy) than is typically seen with beta-emitter-labeled antibodies. In a murine dose-escalation study, 120 absorbed doses of up to 400
Gy were intraperitoneally given, with posttherapy tumor-free fractions up to 61% with 211 At-MX35 F(abʹ) 2 . An experiment that treated mice with one infusion vs repeated weekly infusions showed a signifi cant improvement in tumor-free status with repeat therapy. 121 In the one published clinical trial of this agent, 9 women with recurrent OC who were in complete remission following salvage systemic therapy were enrolled into a phase I study of intraperitoneal 211 At-MX35 F(abʹ) 2 . 122 No toxicity was observed, and only 6% of the infused dose was measurable in the serum, so the authors concluded that intraperitoneal therapy with 211 At-MX35 F(abʹ) 2 was both feasible and safe for patients with recurrent OC.
Several other potential targets for RIT in OC have been described, but with little or no clinical experience. [123] [124] [125] [126] [127] [128] [129] [130] [131] RIT for OC appears to be a potentially promising option, particularly in patients who have been optimally debulked following surgery and chemotherapy but who still are at high risk for microscopic intraperitoneal disease. Alpha-emitting radionuclides hold particular promise in nonbulky disease, given the higher linear energy transfer and shorter path length compared with beta particles. Therefore, the accrual of ongoing clinical trials of these novel agents should be encouraged.
Pancreatic Cancer
In general, pancreatic cancer (PanC) carries a poor prognosis. In 2012, approximately 43,920 new cases were diagnosed and 37,390 deaths occurred due to this disease. 15, 16 Particularly for unresectable cases, the median survival is shorter than 1 year, with few long-term survivors. The vast majority of PanC cases are mucin-producing adenocarcinomas, making MUC-1 an attractive target for RIT. 132 PAM4 is a murine monoclonal antibody directed against MUC-1, and early preclinical work demonstrated effi cient targeting of PanC xenografts in athymic mice. 133 Initial human studies of patients going for surgical resection used immunoscintigraphy to demonstrate the targeting of the 131 I-radiolabeled PAM4 to PanC tumor cells. 134 Both 131 I-PAM4 and 90 Y-PAM4 showed significant anti-PanC tumor effects in animal models, particularly when given concurrently with gemcitabine as a radiosensitizer. [135] [136] [137] The fi rst human therapeutic trial of the humanized version of the antibody (hPAM4) treated 20 patients with escalating single doses of 90 Y-hPAM4 (15-25 mCi/m 2 ). 138 Objective responses were seen in 3 patients, and PFS was seen up to 5.6 months following treatment. However, most patients progressed within 1 month following RIT. The MTD was determined to be 20 mCi/m 2 for a single infusion. In a phase I/II follow-up study of 100 patients, investigators examined the role of fractionated RIT concurrent with escalating doses of gemcitabine for radiosensitization. 139 They found that the administration of multiple cycles of fractionated RIT was both feasible and safe in patients with advanced PanC. Escalated doses of gemcitabine did not appear to improve responses. SD or objective responses were seen in 58% of the treated patients. Nearly one-half of patients treated with 1 or more cycles of RIT had an OS of longer than 1 year. A randomized trial of 90 Y-hPAM4 with or without gemcitabine is currently in development to determine the role of the addition of the radiosensitizing agent.
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Hepatocellular Carcinoma
Primary liver cancer is diagnosed in more than 500,000 people worldwide each year, including 25,000 in the United States. 15, 16 More than 90% of these are hepatocellular carcinomas (HCCs). 141 Few patients are diagnosed at an early, resectable stage, making long-term survival for most patients poor, with a median survival shorter than 1 year. 142 Early attempts at RIT for unresectable HCC using 131 I-anti-alpha-fetoprotein (AFP) and 131 I-anti-ferritin have yielded mixed results.
2,143,144
131 I-Hepama-1 was the fi rst RIT agent developed to bind to a HCC membrane antigen, and early preclinical studies of human HCC xenografts in nude mice demonstrated that injections of the antibody led to objective responses and improved survival compared with controls. 145 A phase I dose-escalation trial 146 of the antibody in patients with unresectable HCC examined doses from 20 to 100 mCi. The treatments were well tolerated by all patients, and the 1-year OS rate was reported to be 31% (60% for patients without metastases). Three-fourths of patients with elevated AFP levels exhibited a 50% or greater reduction in the tumor marker. The HCC-associated membrane antigen HAb18G/ CD147 has also been identifi ed as a potential RIT target, using the monoclonal antibody F(abʹ) 2 fragment 131 I-metuximab as a hepatic artery infusion. A phase I/II study determined the MTD to be 0.75 mCi/kg body weight per cycle and, of the 73 patients receiving 2 cycles of RIT, 20 had objective responses and 43 exhibited SD in response to therapy. 147 Median OS was 19 months. In a separate report, the group demonstrated highly specifi c tumor-to-normal-tissue absorbed doses.
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Central Nervous System
The blood-brain barrier hinders the transport of most large molecules such as proteins from entering the central nervous system (CNS). Although tumor-initiated angiogenesis may result in more permeable microvasculature, this is typically not suffi cient to allow for signifi cant delivery of antibodies and antibody fragments to the CNS. 149 The addition of external beam radiotherapy can further disrupt the blood-brain barrier by increasing the vascular permeability. [150] [151] [152] Most attempts at RIT for CNS malignancies have focused on direct intratumoral or intracavitary administration.
Perhaps the target most investigated for CNS tumors is tenascin, a glycoprotein concentrated within the extracellular matrix of malignant gliomas. 153 Riva et al 154 fi rst reported on antitenascin RIT in a study of 10 patients with recurrent glioblastoma (GBM) who received intratumoral administration of 131 I-BC-2, a murine monoclonal antibody directed against tenascin. The mean specifi c activity per injection was approximately 15 mCi, and most patients received multiple injections. Cumulative tumor doses ranged from 70 to 410 Gy. The injections were well tolerated without systemic effects. Responses included 1 patient with CR, 2 with PRs, and 3 with SD, and all responders were relapse-free for at least 11 months. 154 In a separate report by the same group of 24 patients with relapsed gliomas, antitenascin RIT was given in doses from 15 to 57 mCi, with up to 4 repeated doses. 155 No signifi cant toxicities were observed, and the median survival was 16 months. Of 17 evaluable patients, 3 reported a CR, 3 had a PR, and 5 had SD.
Riva et al 156 also examined the role of 131 I antitenascin RIT in patients with newly diagnosed malignant gliomas following surgical resection and chemoradiotherapy in a study of 50 patients: 26 had recurrent disease and 24 had been newly diagnosed. Patients received up to 6 repeated infusions, with doses up to 300 Gy per infusion. The median OS was 20 months for all patients (18 for relapsed disease and 23 for the newly diagnosed), with a 40% overall response rate. The group later performed a phase I study of 90 Y-BC-4, another antitenascin murine antibody, in 20 patients with recurrent high-grade gliomas. 157 Doses ranged from 5 to 30 mCi with an MTD of 25 mCi. The mean tumor dose was 3200 cGy/mCi, and no systemic toxicity was seen. The use of 90 Y demonstrated improved responses compared with 131 I for bulky residual disease and with fewer radioprotection concerns due to the lack of gamma emissions. 158 Another antitenascin radiolabeled monoclonal antibody, 131 I-81C6, was evaluated in a phase 1 study in 34 patients with previously irradiated glioma who also had surgically created resection cavities. 159 Doses ranged from 20 to 120 mCi, with the MTD determined to be 100 mCi. Neurologic toxicity was dose limiting, with signifi cant hematologic toxicity seen only at the 120 mCi level, and median survival for all treated patients was 60 weeks. The same group reported the results of a phase I study in patients who were newly diagnosed with malignant glioma following surgery and had not received additional adjuvant therapy. 160 Doses ranged from 20 to 180 mCi with, an MTD of 120 mCi. DLT was primarily delayed neurotoxicity. One patient required surgery for symptomatic radiation necrosis. Median survival for all patients was 79 weeks. In a follow-up phase II trial in 33 patients with newly diagnosed high-grade glioma receiving 120 mCi 131 I-81C6 followed by adjuvant chemoradiation, the median OS was 86.7 weeks for all patients and 79.4 weeks for those with GBM. 161 A dosimetric analysis from this trial suggested that the tumor cavity absorbed a dose of 44 Gy provided optimal clinical outcomes. 162 A phase II study in 43 patients with recurrent disease receiving 100 mCi 131 I-81C6 showed median survivals of 99 and 64 weeks for anaplastic and GBM patients, respectively. 163 A phase I study of a chimeric construct of 131 I-81C6 reported an MTD of 80 mCi and suggested greater hematologic toxicity than was seen with the murine antibody. 164 The epidermal growth factor receptor (EGFR), a transmembrane glycoprotein, is expressed in a variety of tissues and its expression in gliomas increases in conjunction with grade, and it is present in a majority of cases of GBM. 165 Early evidence of the effi cacy of anti-EGFR RIT was reported in a pilot study by Brady et al. 166 A total of 15 patients with recurrent malignant glioma were treated with 125 I-labeled anti-EGFR-425, given intra-arterially via either the carotid or vertebral arteries. They reported 1 CR, 2 PRs, and 5 patients with SD in response to treatment. The same group performed a phase II trial of 125 I-425 in 25 patients with multiple infusions and cumulative doses, ranging from 40 to 224 mCi, following surgical resection and adjuvant external beam radiotherapy. 167 Median survival was reported to be 15.6 months, with more than 60% of patients alive at 1 year. Recently, Li et al 168 published the results of a phase II trial of 125 I-425, with or without temozolomide, in 192 patients with GBM following surgical resection. Median survival following RIT alone was 14.5 months vs 20.2 months for the temozolomide arm, representing a 38% reduction in the risk of death with the addition of concurrent chemotherapy.
Leptomeningeal disease (LMD) represents a unique form of CNS malignancy, and intraventricular administration of RIT has been investigated in several studies. Kramer et al 169 reported on the use of 131 I-3F8, a murine monoclonal antibody directed against disialoganglioside (GD2). Five patients with LMD expressing GD2 received intraventricular administration of 1 to 2 mCi of 131 I-3F8. Single-photon emission computed tomography imaging predicted doses of 15 to 56 cGy/mCi to the cerebral spinal fl uid (CSF) compared with less than 2 cGy/mCi to extracranial tissues. In a formal phase I study of intraventricular 131 I-3F8, 15 patients with GD2+ LMD received from 10 to 20 mCi after acceptable CSF fl ow was demonstrated with a dosimetric dose. 170 The total dose to the CSF ranged from 1 to 13 Gy. DLT was seen at the higher dose level, including chemical meningitis, and, of the 13 assessable patients, 3 exhibited a CR and 2 remained in remission for at least 3.5 years.
Antitumor Necrosis Therapy
Although most RIT approaches have endeavored to target specifi c tumor membrane antigens, one alternative is to target regions of tumors undergoing necrosis, either secondary to therapy or to degeneration. These dead and dying cells exhibit increased permeability of the cell membrane, and previous studies have shown increased uptake of circulating proteins. 171, 172 Epstein et al 173 reported on the development of monoclonal antibodies directed against the DNA-histone H1 complex seen in dying cells. Tumor-bearing nude mice were injected with 131 I-TNT-1, an F(abʹ) 2 IgG fragment, and necrotic tumor-to-blood ratios were greater than 100:1, showing highly specifi c accumulation in areas of tumor necrosis. Since that early report, radiolabeled TNT-1 has been investigated in a number of malignancies, including cervical, colon, brain, and lung cancers as well as hepatic metastases. [174] [175] [176] [177] [178] [179] The antibody was approved by the Chinese State Food and Drug Administration in 2003 for the treatment of advanced lung cancer, and it appears to have little immunogenicity in clinical practice.
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Conclusions
Signifi cant advancements have been made in the development of RIT during the last 60 years. Progress in chimerization and humanization of monoclonal antibodies, the use of antibody fragments, pretargeting methods, improved dosimetric models, and novel radionuclides -including alpha-emitters -have opened the fi eld beyond simply B-cell non-Hodgkin lymphomas. Several new RIT agents are under active clinical investigation for many solid tumor types. Many of these are entering phase II and III clinical trials, and physicians and their patients with cancer should be encouraged to consider participating in these important endeavors. 181 
